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Abstract
Introduction
The coronary artery disease-reporting and data system (CAD-RADS) was developed to
standardize communication of per-patient maximal stenosis and provide treatment
recommendations that may affect downstream testing.

Methods
Downstream testing, cardiology referral, and cost were abstracted for 1,796 consecutive
patients undergoing coronary CT angiography (CCTA) before and after the adoption of the
CAD-RADS reporting template at a single-center closed referral hospital system. Cost analysis
was based on direct invasive and non-invasive testing utilizing the Center for Medicare &
Medicaid Services (CMS) outpatient prospective payment system (OPPS) final rule for 2018.

Results
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Baseline cardiovascular risk factors were balanced between the groups. Overall, referrals for
downstream testing were similar between cohorts (10.7% vs 10.8%; p = 0.939). Referral for
downstream testing was reduced in the CAD-RADS 1 & 2 cohort compared to non-obstructive
coronary artery disease (CAD) by non-standardized reporting (NSR; 5.1% vs 14.4%, p < 0.001).
This was offset by more non-diagnostic scans in the CAD-RADS cohort (9.7% vs 4.2%, p <
0.001), resulting in increased downstream testing (28.8% vs 11.4%, p = 0.038). Overall,
cardiology referral rates by primary care providers (PCPs) were similar between the groups
(12.2% vs 15.8%, p = 0.197). Cardiology referral rates were increased among patients with nonobstructive CAD in the NSR cohort compared with CAD-RADS 1 & 2 patients (20.5% vs 8.6%,
p = 0.021). Referrals for invasive coronary angiography were low in both groups overall (3.5% vs
3.2%, p = 0.726). Median downstream testing costs were similar between the groups (p = 0.554).
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Adoption of the CAD-RADS reporting template was associated with a reduction in downstream
testing and cardiology referral rates among non-obstructive CAD (CAD-RADS 1 & 2) patients.
Thus, CAD-RADS may impact downstream testing in patients in whom further testing can
typically be deferred.
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Introduction
Coronary CT angiography (CCTA) is well-validated as an initial test in patients without known
coronary artery disease (CAD) presenting with acute and stable chest pain [1-7]. The primary
advantage of CCTA in this population is the ability to exclude significant CAD given its near
100% negative predictive value. Conversely, the inability to determine the functional
significance of intermediate grade lesions has historically resulted in increased rates of referral
for invasive coronary angiography (ICA) and revascularization. In the acute chest pain
population, CCTA was observed to increase ICA rates revascularization rates compared with
usual care [8]. Similarly, a trend toward increased ICA rates and significantly higher rates of
revascularization following CCTA in the stable chest pain population were observed in a metaanalysis incorporating the four randomized controlled trials performed to date [9]. This data led
to concern among payers and policymakers that CCTA may simply increase cost over functional
testing. More recently, CCTA was adopted as the preferred first-line test in the National
Institute for Health and Care Excellence (NICE) guidelines for the evaluation of typical and
atypical angina in patients without known CAD in the United Kingdom (UK). This
recommendation was based, in large part, on an analysis performed by independent economists
evaluating the incremental cost and care benefit of various diagnostic strategies. They found
that the cost of CCTA would have to triple before it would lose its cost-effectiveness advantage
with respect to cost per correct diagnosis [10].
The role of the imaging report is vital to communicating pertinent test findings to the referring
provider so that appropriate interventions can be pursued. The American College of Radiology
(ACR) states that effective communication of important imaging findings should promote
optimal patient care, support the ordering provider, be tailored to satisfy the need for
timeliness, and minimize the risk of communication errors [11]. Data from the Study of
Myocardial Perfusion and Coronary Anatomy’s Roles in Coronary Artery Disease (SPARC)
demonstrated that referral for invasive coronary angiography was <10% and less than half of
patients with the highest risk imaging findings were prescribed anti-anginal medications,
aspirin, and lipid-lowering agents at 90 days following the index functional stress test or CCTA
[12]. Coronary artery disease-reporting and data system (CAD-RADS™) was developed to
bridge the communication gap between the cardiac CT imaging specialist and the ordering
provider with a goal of concise disclosure of imaging results in a standardized fashion linked
with recommended therapeutic interventions [13]. We sought to evaluate the impact of CADRADS adoption on downstream testing, referral for cardiology consultation, and direct costs in
a single-center closed referral system.

Materials And Methods
Population
We queried the picture archiving and communication system (PACS) for all CCTAs performed
for clinical purposes between May 1, 2015 and June 30, 2017. CCTAs over a 12-month period
prior to local CAD-RADS adoption were included in the non-standardized reporting (NSR)
cohort. CCTAs performed in the 12 months following CAD-RADS adoption were included in the
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CAD-RADS cohort. A two-month window was excluded between the two cohorts to account for
variable rates of adoption among imaging providers. CCTAs performed for reasons other than
the evaluation of coronary atherosclerosis were excluded (Figure 1). Baseline demographic data
were obtained through chart abstraction of a comprehensive electronic medical record (EMR)
system. Hypertension was defined as a diagnosis of hypertension or utilization of an
antihypertensive medication prior to CCTA. Hyperlipidemia was defined as a fasting LDL >190
mg/dL, a diagnosis of dyslipidemia in the EMR, or treatment with lipid-lowering medication.
Diabetes mellitus was defined as a hemoglobin A1c ≥6.5% or prescription of anti-hyperglycemic
medications. Patients with prior myocardial infarction (MI), percutaneous coronary
intervention (PCI), or coronary artery bypass graft (CABG) surgery prior to CCTA were excluded
for this analysis. Active smoking was adjudicated based on smoking status as documented in
the provider encounter during which the CCTA was ordered. The medical specialty of the
ordering provider was also abstracted, along with the rate of downstream testing and
cardiology referrals following CCTA.

FIGURE 1: Study subject flow chart
Cardiac computed tomography (CCT) scans for 2,000 total patients obtained before and after the
adoption of CAD-RADS were screened. CCT scans performed for EP planning purposes,
congenital heart disease, transcatheter aortic valve replacement planning, evaluation of new
cardiomyopathy or heart failure, other thoracic vascular assessments, and preoperative scans were
excluded. Additionally, scans in which the coronary CT angiogram was canceled due to very high
coronary artery calcium (CAC) score were excluded. The remaining cohort was organized by
maximum per-patient coronary stenosis or CAD-RADS as applicable.
CCT, cardiac computed tomography; EP, electrophysiology; HF, heart failure; CMP,
cardiomyopathy; CAC, coronary artery calcium; CAD, coronary artery disease; CCTA, coronary
computed tomography angiography; CAD-RADS, coronary artery disease reporting & data system

Coronary CT angiography
All CCTAs were performed in accordance with the published guidelines utilizing either a 128slice dual-source CT scanner (Definition Flash CT, Siemens Healthcare) or a 320-slice CT
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scanner (Aquilion ONE Vision, Toshiba Medical Systems) [14]. Coronary artery calcium (CAC)
acquisitions were performed on all patients ≥40 years of age at the discretion of the CT
technologist and imaging provider and interpreted utilizing the Agatston method [15]. Image
interpretation was performed on a 3D workstation (Vital Images, Inc) by a level II or III cardiac
imaging cardiologist or radiologist [16-17]. During the study period, all CCTAs were interpreted
by the same cohort of cardiologists with the exception of one additional cardiologist prior to
the adoption of CAD-RADS.

Coronary CT angiography reporting
CCTA scans performed prior to CAD-RADS implementation were interpreted and reported in
accordance with previously published societal guidelines [18]. A normal scan was free of plaque
or stenosis with a CAC score of zero (if performed). Non-obstructive CAD was defined as
maximal per-patient stenosis between 1% and 49% or any CAC, and obstructive CAD was
defined as a maximal per-patient stenosis ≥50%. The inclusion of recommendations from the
cardiac imaging specialist in the report was at the discretion of the interpreting provider and
was performed rarely in the NSR cohort. The imaging report format in the CAD-RADS cohort
was modeled after the recommended template included in the published document (Table 1)
[13]. Thus, a similar per-patient conclusion statement was reported: normal (no plaque/CAC
zero/CAD-RADS 0), minimal (<25% stenosis/CAD-RADS 1) or mild (25% to 49% stenosis/CADRADS 2) non-obstructive CAD, and moderate (50% to 69% stenosis/CAD-RADS 3) or severe
(70% to 100% stenosis/CAD-RADS 4/5) obstructive CAD. Additionally, the corresponding
recommendation for stable chest pain was included in the report for all patients. In cases where
the CCTA was performed for acute chest pain, the corresponding CAD-RADS statement
pertaining to the likelihood of acute coronary syndrome (ACS) based on the CCTA findings was
also included.

CAD-RADS ™

0

1

2

3

4

5

N

1% to 24%
0% (No

A: 70% to 99% B: LM

Non-

(Minimal stenosis
Maximal Stenosis

plaque or

25-49%

50-69%

>50% or 3v obstructive

100%

diagnostic

or plaque with no
stenosis)

disease

Study

stenosis)

Cannot
Conclusion

ACS Highly Unlikely

ACS Unlikely

ACS Possible

ACS Likely

ACS Very Likely

exclude
ACS

None unless high
clinical suspicion

Consider hospital
Additional

or high-risk

Consider hospital

admission with

Consider expedited ICA

plaque features,

admission with

Cardiology consultation.

on a timely basis and

then consider

Cardiology

Further evaluation with

revascularization if

hospital

consultation and/or

ICA and

appropriate if acute

admission with

ICA

revascularization as

occlusion.

or
Recommended

alternative
None

None

Intervention

evaluation
for ACS is
needed
Cardiology

appropriate.

consultation
Acute
Chest

Consider the

Pain

evaluation of
non-ACS
etiology, if
No further

normal troponin

Consider the
evaluation of nonACS etiology, if
normal troponin

Recommendation for
anti-ischemic and
preventive
management should

Recommendation for

Recommendation for

and no ECG

2019 Boster et al. Cureus 11(9): e5708. DOI 10.7759/cureus.5708

4 of 13

Management

evaluation of

and no ECG

ACS is

changes.

required.

Consider referral

Consider other

for outpatient

etiologies.

follow-up for
preventive
therapy and risk
factor

changes.
Consider referral
for outpatient
follow-up for
preventive
therapy and risk
factor
modification.

be considered as well

anti-ischemic and

anti-ischemic and

as risk factor

preventive management

preventive management

modification. Other

should be considered as

should be considered as

treatments should be

well as risk factor

well as risk factor

considered if the

modification.

modifications.

presence of
hemodynamically
significant lesion.

modification.

Cannot
Absence of

Minimal non-

Mild non-

CAD

obstructive CAD

obstructive CAD

Conclusion

Exclude
Moderate stenosis

Severe stenosis

Total coronary occlusion
Obstructive
CAD

Additional
or
A: Consider ICA or
Recommended

Consider functional
None

None

None

Intervention

Consider ICA and/or

alternative

viability assessment

evaluation

functional assessment
assessment
B: ICA is recommended
may be
needed

Stable
Consider non-

Chest

Consider symptom-

Consider symptom-

guided anti-ischemic

guided anti-ischemic

and preventive

and preventive

pharmacotherapy as

pharmacotherapy as

well as risk factor

well as risk factors

modification per

modification per

guideline-directed care.

guideline-directed care.

Other treatments

Other treatments

(including options of

(including options of

revascularization)

revascularization)

should be considered

should be considered

per guideline-directed

per guideline-directed

care.

care.

Consider symptomatherosclerotic

Pain

guided anti-ischemic
causes of chest
Consider non-

and preventive
pain. Consider

Reassurance.

atherosclerotic

pharmacotherapy as
preventive

Consider

causes of chest

well as risk factor
therapy and risk

non-

pain. Consider

Management

modification per
factor

atherosclerotic

preventive

causes of

therapy and risk

guideline-directed
modification,
care. Other
particularly for

chest pain.

factor

treatments should be
patients with non-

modification.

considered per
obstructive
guideline-directed
plaque in multiple
care.
segments.

TABLE 1: CAD-RADS reporting recommendations
LM, left main coronary artery; ACS, acute coronary syndrome; ICA, invasive coronary angiography; ECG, electrocardiogram; CAD,
coronary artery disease; CAD-RADS, coronary artery disease-reporting & data system

Downstream testing & subspecialty referral
Given the short duration of follow-up time from the date of CCTA in both cohorts, any
downstream ischemic testing was considered related to CCTA. Exercise treadmill stress, stress
echocardiography (exercise or dobutamine), vasodilator stress cardiac magnetic resonance, and
single-photon emission computed tomography (SPECT) myocardial perfusion imaging
(exercise or vasodilator) were considered downstream functional testing. Invasive coronary
angiography (ICA) or repeat CCTA was considered downstream anatomic testing. The initial
telephone or in-person provider note following CCTA was reviewed. Cardiology referrals placed
during this visit were considered related to CCTA.
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Cost analysis
Cost analysis was based on direct patient charges utilizing the Center for Medicare & Medicaid
Services (CMS) outpatient prospective payment system (OPPS) final rule for 2018. Noninvasive testing costs were based on the following CPT codes: 77574, 78452, 93351, 75563, and
93015. ICA with left heart catheterization (LHC) was utilized when invasive fractional flow
reserve (FFR) and percutaneous coronary intervention (PCI) was deferred. The incremental cost
for the performance of invasive FFR and PCI was included when applicable.

Statistical analysis
Statistical analysis was performed using IBM SPSS version 22.0 (IBM, Armonk, NY) and JMP
version 13.3 (SAS Corp, Cary, NC). Parametrically distributed continuous variables are reported
as means with standard deviation and nonparametric data are reported as medians with
interquartile range. Comparison between continuous variables was performed utilizing a 2tailed Fisher’s exact test or a Wilcoxon Rank-sum test, as appropriate. A Bonferroni correction
was applied when appropriate.

Results
Population
The CAD-RADS reporting template was utilized in 83.7% of CCTAs performed during the CADRADS adoption period. In asymptomatic patients undergoing CCTA, NSR was more frequently
used (p = 0.033). The ordering provider was more commonly a primary care provider in the NSR
cohort (p = 0.047), whereas CAD-RADS was more commonly utilized in studies ordered by a
cardiology provider (p = 0.003). Baseline cardiovascular risk factors were well balanced between
the groups (Table 2).

CAD-RADS Cohort (n = 751)

NSR Cohort (n = 1045)

p-value

ATCP

612 (81.5%)

823 (78.8%)

0.159

Dyspnea

20 (2.7%)

34 (3.3%)

0.465

Syncope

22 (2.9%)

25 (2.4%)

0.656

Abnormal Stress Test

11 (1.5%)

29 (2.8%)

0.067

Acute CP/ED CT

32 (4.3%)

28 (2.7%)

0.064

Asymptomatic

54 (7.2%)

106 (10.1%)

0.033

Age

50±12

49±13

0.133

Male gender

446 (59.4%)

577 (55.2%)

0.082

Active Smokers

94 (12.5%)

165 (15.8%)

0.057

Diabetes

111 (14.8%)

137 (13.1%)

0.332

HTN

364 (48.5%)

499 (47.8%)

0.774

Dyslipidemia

333 (44.3%)

468 (44.8%)

0.885

Study Indications
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Known CHD

53 (7.1%)

77 (7.4%)

0.854

Normal

360 (47.9%)

595 (56.9%)

<0.001

Non-obstructive CAD

247 (32.9%)

334 (32.0%)

0.689

Obstructive CAD

29 (3.9%)

51 (4.9%)

0.313

Non-diagnostic Scan/Segment

73 (9.7%)

44 (4.2%)

<0.001

Any CAD

276 (36.8%)

385 (36.8%)

1.000

CAC score (median, IQR25,75)

0 (0, 24.5)

0 (0, 22)

0.114

CAC percentile

76.7±18.3

78.2±18.0

0.288

Incidence CAC > 75th percentile

177 (26.0%)

213 (22.4%)

0.099

Statin

277 (36.9%)

358 (34.3%)

0.271

Non-statin

34 (4.5%)

55 (5.3%)

0.510

ASA

267 (35.6%)

352 (33.7%)

0.421

Antihypertensive

342 (45.5%)

482 (46.2%)

0.810

CCTA CAD burden

Baseline Medical Therapies

TABLE 2: Baseline demographic data
NSR, non-standardized reporting; ATCP, atypical chest pain; CP, chest pain; ED, emergency department; CT, computed tomography;
HTN, hypertension; CHD, coronary heart disease; CAD, coronary artery disease; CAC, coronary artery calcium; IQR, interquartile
range; ASA, aspirin; CAD-RADS, coronary artery disease-reporting & data system

Downstream testing
Referrals for additional downstream testing (Figure 2) were similar between the CAD-RADS and
NSR cohorts (10.7% vs 10.8%, p = 0.939). The rates of referral for downstream functional testing
and anatomic testing were also similar (p = 0.276 & 0.226, respectively). Functional testing was
more commonly performed in all stenosis severity categories with the exception of obstructive
CAD/CAD-RADS 3-5 (Figure 2). In patients with no CAD, downstream testing referrals were
rare (3.3% vs 2.2%, p = 0.300), driven almost entirely by functional testing (88.0% vs 92.3%, p =
0.593). Among patients with non-obstructive CAD, referral for downstream testing (Figure 2)
was reduced in CAD-RADS 1 & 2 patients compared to NSR (5.1% vs 14.4%, p < 0.001).
Downstream testing was numerically lower in CAD-RADS 3 through five patients compared
with obstructive CAD in the NSR cohort (49.4% vs 65.3%, p = 0.052). These were offset by a
higher incidence of CAD-RADS N scans compared to non-diagnostic scans within the NSR
cohort (9.7% vs 4.2%, p < 0.001). The imaging report was significantly more likely to include
recommendation for downstream testing in the CAD-RADS cohort compared to NSR (60% vs.
9.3% p < 0.001). This was associated with an increased observed incidence of downstream
testing (28.8% vs 11.4%, p = 0.038). In both the CAD-RADS and NSR cohorts, non-diagnostic
scans were attributed to poor visualization of epicardial vessels, branch vessels or both at
similar rates (54.8% vs. 50%; 2.7% vs. 11.4%; 42.5% vs. 38.6%, respectively), When excluding
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patients with normal or non-diagnostic CCTAs, downstream testing was more commonly
pursued in the NSR cohort (23.4% vs 15.5%, p = 0.009).

FIGURE 2: Downstream testing rates before and after the
adoption of the CAD-RADS standardized reporting template
Downstream testing in the CAD-RADS (blue) compared with NSR (green) cohorts. The dark color
represents functional testing and the lighter color represents coronary anatomy testing. There were
no differences in functional or anatomic testing rates between CAD-RADS and non-standardized
reporting (NSR) cohorts within each stenosis severity category. Functional testing was far more
common in all categories with the exception of obstructive CAD/CAD-RADS 3-5.
Panel A: Graphical representation of CAD-RADS and NSR cohorts overall and with nonobstructive/non-diagnostic scans; Panel B: Graphical representation of CAD-RADS and NSR
cohorts with obstructive coronary artery disease
CAD-RADS, coronary artery disease-reporting & data system; NSR, non-standardized reporting;
Non-obstr, non-obstructive; N, non-diagnostic

Invasive coronary angiography
Referrals for invasive coronary angiography (ICA) were low in both groups overall (3.5% in
CAD-RADS and 3.2% in NSR, p = 0.726). Among patients referred for ICA, the incidence of
confirmed obstructive CAD was high in both groups (61.5% vs 69.7%, p = 0.585). Among
patients with obstructive CAD, referrals for ICA were similar between the groups (56.1% vs
51.1%, p = 0.638), as was the rate of obstructive CAD on ICA (p = 0.193). Despite lower
downstream testing rates in CAD-RADS patients after excluding those with no CAD and nondiagnostic scans, there was no difference in the incidence of confirmed obstructive CAD on ICA
(74.2% vs 66.7%, p = 0.565).

Referrals to cardiology
After excluding CCTAs ordered by cardiology providers, the rate of cardiology referral by
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primary care providers (PCPs) were similar when comparing the CAD-RADS to NSR cohorts
(12.2% vs 15.8%, p = 0.197). Cardiology referrals, irrespective of reporting template utilized,
were more common among patients with any CAD on CCTA (21.8% vs 9.4%, p < 0.001). In
patients with no CAD, cardiology referrals were low and did not differ between the reporting
template groups (p = 0.431). In patients with obstructive CAD, cardiology referral rates were
higher but again did not differ between the reporting template cohorts (p = 0.865). Conversely,
significantly higher rates of cardiology referrals from PCPs were observed for non-obstructive
CAD in the NSR cohort compared with CAD-RADS 1 & 2 patients (20.5% vs 8.6%, p = 0.021).
Referrals to a cardiology provider were similar between reporting cohorts in patients with nondiagnostic scans/CAD-RADS N (16.0% vs 15.8%, p = 0.984). After excluding patients with
normal or non-diagnostic CCTAs, no difference was observed in the PCP referral rates to
cardiology between the reporting cohorts (CAD-RADS: 16.7% vs NSR: 25.0%, p = 0.107).

Cost analysis
Median downstream total testing costs (Figure 3) were similar when CAD-RADS or NSR
templates were utilized ($1248; $526-$7750 vs $1248; $825-$7750, p = 0.554). When
incorporating cardiology referral costs based on a 99203 encounter with any downstream
testing costs, there was no difference between the groups (p = 0.598). When comparing perpatient maximum stenosis severity categories between the groups, there was no difference in
median total testing costs or testing costs plus cardiology referral costs.

FIGURE 3: Comparison of median downstream testing costs
between the CAD-RADS and non-standardized reporting
cohorts
Spline curve with error bars depicting the median downstream testing costs based on per-patient
maximum coronary stenosis between the CAD-RADS and NSR cohorts. P = NS for all betweengroup comparisons. Downstream testing costs were higher for CAD-RADS N and NSR
nondiagnostic scans compared to patients with no CAD/CAD-RADS 0 and obstructive CAD/CADRADS 3-5 (p < 0.05).
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CAD-RADS, coronary artery disease-reporting & data system; Nonob CAD, non-obstructive
coronary artery disease; Nondiag, non-diagnostic; Obstr CAD, obstructive coronary artery disease;
NSR, non-standardized reporting; USD, United States Dollar

Discussion
Utilization of the CAD-RADS reporting template in a single-center, closed-referral military
health system was not associated with changes in cardiology referral rates among PCPs,
downstream testing, or overall testing costs. However, a reduction in downstream testing and
cardiology referral were observed among patients with non-obstructive CAD by CAD-RADS
(CAD-RADS 1 & 2) compared with NSR. This difference was offset by higher rates of nondiagnostic scans (CAD-RADS N) in the CAD-RADS cohort that resulted in higher downstream
testing rates compared with the NSR cohort. We suspect the higher rate of non-diagnostic scans
observed in the CAD-RADS cohort was secondary to the explicit criteria for non-diagnostic
scans delineated in the CAD-RADS reporting template. This suggests that the adoption of the
CAD-RADS reporting template was associated with increased resource utilization in the nondiagnostic cohort which negated the decrement in downstream testing & cardiology referral
that was observed in the CAD-RADS 1&2 cohort. There was no significant difference in vessel
involvement (epicardial vs. branch vessel) that was attributed to the non-diagnostic scans in
both cohorts which suggests in the NSR cohort the decision to pursue further downstream
testing was a result of the ordering providers interpretation of the data presented. Given these
findings, the adoption of the CAD-RADS template with the inclusion of recommendations for
further downstream testing in the event of a non-diagnostic scan likely contributed to the
observed increase in downstream testing in that cohort. Excluding nondiagnostic scans/CADRADS N, observed downstream testing, and cardiology referrals were reduced when CAD-RADS
was utilized without a reduction in the detection of obstructive CAD on ICA.
Large prospective trials and registry data have described the effect that CCTA has on
downstream testing, ICA and revascularization. All of these studies, with the exception of the
Scottish Computed Tomography of the Heart (SCOT HEART) trial, reported increased rates of
ICA and revascularization [1,19-20]. SCOT HEART notably did report higher rates of ICA and
revascularization in the CCTA group initially, but overall rates were similar at five years. CCTA
utilizing non-standardized reporting systems have been evaluated previously with prior
analyses concluding that CCTA is likely a cost-effective alternative to functional testing [21]. In
fact, an independent economic analysis performed for the NICE guidelines concluded that
CCTA provided the lowest cost per correct diagnosis [10]. Our analysis evaluated the association
of CAD-RADS reporting system adoption on the observed rate of downstream testing,
cardiology referral rates, and invasive coronary angiography. In comparison to prior studies in
which these outcomes were reported in CCTA compared to functional testing, we observed a
lower rate of utilization of downstream testing in patients with non-obstructive disease offset
by higher utilization in patients with nondiagnostic studies. While this did not change the
overall cost or downstream utilization rate, it may represent a reallocation of resources toward
patients must likely benefit from further testing. Importantly, this reduced testing and
cardiology referral rate did not significantly change the incidence of obstructive CAD on ICA in
the CAD-RADS cohort.
The role of the imaging report is vital to communicating pertinent test findings to the referring
provider so that appropriate interventions can be pursued. The primary means by which a
diagnostic imaging test impacts patient outcomes is through effective communication of
important findings to the treating provider. There are several examples of standardized
reporting systems positively impacting patient outcomes, namely the Breast Imaging Reporting
and Data System (BI-RADS) and Liver Imaging Reporting and Data System (LI-RADS) systems
for reporting breast and liver imaging findings, respectively [22-23]. These standardized
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reporting systems have been associated with a reduction in the incidence of reporting errors
and miscommunication, likely as a result of a reduction in interpretation variability [24].
Conversely, a lack of standardized reporting can result in misinterpretation of patient risk and
the potential for under treatment. In the study of Myocardial Perfusion and Coronary Anatomy
Imaging Roles in Coronary Artery Disease (SPARC), roughly 50% of patients with high-risk noninvasive cardiac imaging findings were not referred for ICA. Additionally, up to 30% were not
prescribed aspirin and up to 25% were not prescribed lipid-lowering agents [12]. Our analysis
seems to support that implementation of CAD-RADS standardized reporting effectively directs
providers to pursue testing appropriately in patients with the highest risk findings while
empowering them to defer testing when non-obstructive CAD is present. Further evidence for
improved communication associated with the adoption of the CAD-RADS template was the
observed increase in an appropriately ordered downstream testing and cardiology referrals in
patients who have non-diagnostic CCTAs in the CAD-RADS cohort compared to NSR which
likely represents a decrease in interpretation variability.
Conclusions from this data are limited by the fact that it was derived from a single-center,
closed-loop, single-payer military treatment facility, thus the results may not be applicable to
other healthcare systems. Our data were obtained via retrospective chart review which limits
the ability to establish causality. A higher incidence of non-diagnostic CCTA (CAD-RADS N)
was observed in the CAD-RADS cohort when compared to NSR. A non-diagnostic rate
approaching 10% in the CAD-RADS cohort is high when compared to published CAD-RADS
data which is approximately 4% [25]. The increased non-diagnostic rate in our population may
be explained by a higher proportion of early career CT readers at our institution, patient
parameters, and strict application of the CAD-RADS criteria for non-diagnostic scans which
specifies that a study is non-diagnostic if not all vessel segments >1.5 mm in diameter can be
interpreted with confidence [13]. Finally, there were considerable differences in follow-up
between the reporting cohorts precluding any analysis of cardiovascular outcomes based on
reporting template utilized.

Conclusions
Adoption of the CAD-RADS reporting template was associated with a reduction in downstream
testing and cardiology referral rates among non-obstructive CAD (CAD-RADS 1 & 2) patients.
Thus, CAD-RADS may impact downstream testing in patients in whom further testing can
typically be deferred.
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